General Information
Lilly BDCY DM1
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin compared with Insulin Degludec in Participants with Type 1 Diabetes Treated with Multiple Daily Injection Therapy.
| Protocol | I8H-MC-BDCY |
|---|---|
| Identifier | |
| UID | c22cc3b9-de75-40eb-8538-996dc9577082 |
| Status | Done - Archived |
| Phase | 3 |
| Category | / Adult |
| Launch Year | 2022 |
| NCT Number | - |
| Created | 2022-04-11 12:14 |
| Last Updated | 2024-01-22 22:09 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2023-02-24 | No |
| Enrollment Open | 2022-11-22 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2022-08-05 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-01-29 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Navarrete, Connie | CNavarrete | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
